Retinoblastoma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Retinoblastoma is a rare tumor but is
the most common eye tumor of childhood. Retinoblastoma is a malignant tumor of
the developing retina that occurs in children, usually before age five years.
Retinoblastoma develops from cells that have cancer-predisposing variants in
both copies of RB1. Retinoblastoma may be unifocal or multifocal. About 60% of
affected individuals have unilateral retinoblastoma with a mean age of diagnosis
of 24 months; about 40% have bilateral retinoblastoma with a mean age of
diagnosis of 15 months. Heritable retinoblastoma is an autosomal dominant
susceptibility for retinoblastoma. Individuals with heritable retinoblastoma
are also at increased risk of developing non-ocular tumors. When it remains
localized to the eye, the prognosis is excellent for long-term survival,
whereas metastatic retinoblastoma is an aggressive malignant neoplasm with poor
survival rates. Through this experience, retinoblastoma has been found to have
a strong genetic component. Some cases, especially those with both eyes
involved, have exhibited an autosomal dominant inheritance pattern. The
treatment of retinoblastoma is multidisciplinary, aims at saving lives and
preserving vision. The intraocular disease is highly curable more than 90% of
patients survive.
- The average age-adjusted incidence rate of retinoblastoma in
the United States varies between 1 to 1.25 cases in 15,000 live births
with a survival rate of 97% to 99%.
Thelansis’s “Retinoblastoma Market
Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2021 To 2032" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Retinoblastoma
treatment modalities options for eight major markets (USA, Germany, France,
Italy, Spain, UK, Japan, and China).
KOLs insights
of Retinoblastoma across 8 MM market from the centre of Excellence/ Public/
Private hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Retinoblastoma Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment